"Organize your Events at OMICS Group Conferences"

Proposals are invited for organizing Symposia/Workshops at OMICS Group Conferences or OMICS Group will sponsor small events at your universities in related areas under the title of your own. These proposals can be sent to respective conference mail ids or to symposia@omicsonline.org.

OMICS Group Conferences
5716 Corsa Ave., Suite 110, Westlake Los Angeles, CA 91362-7354, USA
Phone: +1-650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
Email: vaccines2014@omicsonline.net
# Day 1

**September 24, 2014 @ Auditorium 3A**

## 08:30-09:00

Registrations

---

### Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30-09:35</td>
<td>Introduction</td>
<td>Ray Spier</td>
<td>University of Surrey, UK</td>
</tr>
<tr>
<td>09:35-10:00</td>
<td>Ray Spier</td>
<td>University of Surrey, UK</td>
<td></td>
</tr>
<tr>
<td>10:00-10:25</td>
<td>Michael G. Hanna</td>
<td>Vaccinogen, Inc., USA</td>
<td></td>
</tr>
<tr>
<td>10:25-10:50</td>
<td>Nikolai Petrovsky</td>
<td>Flinders Medical Centre Research, Australia</td>
<td></td>
</tr>
</tbody>
</table>

---

### Vaccine adjuvants

**Session Chair:** Nikolai Petrovsky, Flinders Medical Centre Research, Australia

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15-11:35</td>
<td>Inter-bilayer cross-linked multi-lamellar vesicles (ICMVs) for efficient co-delivery of antigen and adjuvant payloads</td>
<td>Alan R Shaw</td>
<td>Veddanta Pharmaceuticals, USA</td>
</tr>
<tr>
<td>11:35-11:55</td>
<td>Adjuvant-guidance of T cell responses</td>
<td>Magdalena Tary-Lehmann, Cellular Technology, USA</td>
<td></td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>Antibody targeting of human T cell CD27 identifies genes and pathways related to inflammation</td>
<td>Venky Ramakrishna</td>
<td>CellEx Therapeutics, USA</td>
</tr>
<tr>
<td>12:15-12:35</td>
<td>Evaluation of ZOSTAVAX® via the intradermal route using the MicronJet™</td>
<td>Brian K. Meyer</td>
<td>Merck &amp; Co, USA</td>
</tr>
<tr>
<td>12:35-12:55</td>
<td>Universal influenza vaccines: Prevention of infection against matched and mismatched strains</td>
<td>Harry Kleanthous</td>
<td>Sanofi-Pasteur, Inc., USA</td>
</tr>
<tr>
<td>12:55-13:15</td>
<td>DNA vaccines which encode natural adjuvants are more effective than canonical DNA vaccines</td>
<td>Eric James Gowans</td>
<td>The University of Adelaide, South Australia</td>
</tr>
</tbody>
</table>

---

### Lunch Break 13:15-14:00 @ Multi Purpose Hall 2

---

## 14:00-14:20

Title: Immune memory resilience, a new way of evaluating adjuvants

Jean-Pierre Y. Scheerlinck, The University of Melbourne, Australia

---

## 14:20-14:40

Title: Novel lipid based adjuvants and delivery systems for induction of CD8 T cell immunity

Lakshmi Krishnan, National Research Council-Human Health Therapeutics, Canada

---

## 14:40-15:00

Title: Establishment of lipid-based immunogens for the development of novel subunit vaccines

Chih-Hsiang Leng, National Health Research Institutes, Taiwan

Title: Highly immunogenic C-terminal binding domain of Clostridium difficile toxin a stimulates dendritic cell maturation

Pele Choi-Sing Chong, National Health Research Institutes, Taiwan

---

## 15:00-15:20

Coffee Break 15:20-15:35 @ Auditorium 3 Foyer

---

## 15:35-15:55

Title: The Cronobacter sakazakii ESP2949-1 phage induces dendritic cell maturation via activation of nuclear factor-κB and IL-12p40 in murine bone marrow

Hyo-Ihl Chang, Korea University, Korea

---

## 15:55-16:15

Title: Nasal administration of antigens using maltodextrin nanoparticles: A mechanistic study

Didier Betbeder, University of Lille2, France

Title: Stabilized liposomes carrying bee venom new formulation is the breakthrough of pain and anaphylaxis and death in mice under venom immunotherapy

Maria Helena Bueno da Costa, Scientific Consultant, France

---

## 16:15-16:35

Title: Live vaccine for equine influenza on the base of cold-adapted recombinant strain A/HK/

Sandybayev Nurlan, Research Institute for Biological Safety Problems, Republic of Kazakhstan

Title: Polio outbreak in the Middle East: Update

Randa Hamadeh, Ministry of Public Health, Lebanon
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15-17:35</td>
<td>Outer membrane vesicle of bacteria: Friend or Foe?</td>
<td>Seyed Davar Siodat</td>
<td>Pasteur Institute of Iran, Iran</td>
<td></td>
</tr>
<tr>
<td>17:35-17:55</td>
<td>Adjuvant properties of outer-membrane-vesicle in hepatitis B surface based vaccine</td>
<td>Arfa Moshiri</td>
<td>Shahid Beheshti University of Medical Sciences, Iran</td>
<td></td>
</tr>
<tr>
<td>17:55-18:15</td>
<td>Role of interferon gamma as immune adjuvant in Labeor ohita</td>
<td>Megha Kadam Bedekar</td>
<td>Central Institute of Fisheries Education, India</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td></td>
<td></td>
<td>18:15-18:25</td>
</tr>
<tr>
<td></td>
<td>Session-II @ Committee Room 6-7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biodefense vaccine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Leonard A Smith, United States Army Medical Research Institute of Infectious Diseases, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15-11:35</td>
<td>Finding a safe, efficacious and stable vaccine in the ricin protein fold</td>
<td>Leonard A Smith</td>
<td>United States Army Medical Research Institute of Infectious Diseases, USA</td>
<td></td>
</tr>
<tr>
<td>11:35-11:55</td>
<td>A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome delivered by intramuscular electroporation</td>
<td>Connie S Schmaljohn</td>
<td>United States Army Medical Research Institute of Infectious Diseases, USA</td>
<td></td>
</tr>
<tr>
<td>11:55-12:15</td>
<td>available for updating smallpox preparedness plans</td>
<td>Nathaly Arndtz-Wiedemann</td>
<td>Bavarian Nordic GmbH, Germany</td>
<td></td>
</tr>
<tr>
<td>12:15-12:35</td>
<td>A vaccine pipeline: Using phage display for identification of immunogenic proteins and generation of human antibodies for diagnostics and therapy</td>
<td>Michael Hust</td>
<td>Technische Universität Braunschweig, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td></td>
<td></td>
<td>12:35-12:45</td>
</tr>
<tr>
<td></td>
<td>Lunch Break 12:45-13:30 @ Multi Purpose Hall 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Veterinary vaccines</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session Chair: Jean L Patterson, Texas Biomedical Research Institute, USA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30-13:50</td>
<td>Quality and consistency of cell culture media with a highlight on FMDV</td>
<td>Serge Oheres</td>
<td>Merck Millipore, France</td>
<td></td>
</tr>
<tr>
<td>13:50-14:10</td>
<td>Vaccine development at animal biosafety level four: Standards and challenges</td>
<td>Jean L Patterson</td>
<td>Texas Biomedical Research Institute, USA</td>
<td></td>
</tr>
<tr>
<td>14:10-14:30</td>
<td>Low dose antigen exposure in extreme early life promotes adaptive immune response in lambs</td>
<td>and piglets</td>
<td>University of Saskatchewan, Canada</td>
<td></td>
</tr>
<tr>
<td>14:30-14:50</td>
<td>Study immune correlates of vaccine-induced protective immunity against rotavirus infection</td>
<td>Lijuan Yuan</td>
<td>Virginia Polytechnic Institute and State University, USA</td>
<td></td>
</tr>
<tr>
<td>14:50-15:10</td>
<td>Targeting aminopeptidase N on enterocytes rapidly induces an IgA response in a pig model</td>
<td>Eric Cox</td>
<td>Ghent University, Belgium</td>
<td></td>
</tr>
<tr>
<td>15:10-15:30</td>
<td>Use of ORF-1 product Rep in prevention and diagnosis of porcine circoviruses</td>
<td>Silvia Pellicer</td>
<td>World Pathol, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coffee Break 15:30-15:45 @ Auditorium 3 Foyer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45-16:05</td>
<td>Properties of ghost bacterial cells obtained by hybrid material with silver nanoparticles (PVA / AgNps) as well as their opportunities for use in vaccine prophylactics</td>
<td>Daniela Pencheva</td>
<td>Bul Bio - NCIPD Ltd, Bulgaria</td>
<td></td>
</tr>
<tr>
<td>16:05-16:25</td>
<td>Readings in commercial Irish dairy herds</td>
<td>Riona Sayers</td>
<td>Animal &amp; Grassland Research and Innovation Center, Ireland</td>
<td></td>
</tr>
<tr>
<td>16:25-16:45</td>
<td>Construction of Phix174 gene E mediated lysis system for generation of Salmonella Enteritidis ghost, and its evaluation as a vaccine candidate for the immunogenicity and protective efficacy against avian salmonellosis</td>
<td>Chetan V. Jawale</td>
<td>Chonbuk National University, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>16:45-17:05</td>
<td>Use of viral interference against avian influenza and establishment of protection levels in field outbreaks in Mexico</td>
<td>Inkar Castellanos</td>
<td>Viren SA de CV, Mexico</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td></td>
<td></td>
<td>17:05-17:15</td>
</tr>
<tr>
<td></td>
<td>Day 2 September 25, 2014 @Auditorium 3A</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Keynote Forum</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00-09:05</td>
<td>Introduction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:05-09:30</td>
<td>Geert Vanden Bossche</td>
<td>UNIVAC LLC, Belgium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30-09:55</td>
<td>Jeffrey Ulmer</td>
<td>Novartis Vaccines &amp; Diagnostics, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Group Photo</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Therapeutic vaccines for chronic infections

**Session Chair:** Jeffrey Ulmer, Novartis Vaccines & Diagnostics, USA

10:05-10:25  
**Title:** Mimogen—a new strategy for post-exposure vaccine development  
**Yuzhang Wu,** Third Military Medical University, China

10:25-10:45  
**Title:** Generation of robust immunity following DNA vaccine immunization enhanced by intradermal electroporation  
**Kate E. Broderick,** Inovio Pharmaceuticals, USA

10:45-11:05  
**Title:** M2SR, a robust flu vaccine with long-lasting, cross-protective immunity  
**Pamuk Bilisel,** Flugen Inc., USA

**Coffee Break 11:05-11:20 @ Auditorium 3 Foyer**

11:20-11:40  
**Title:** In vivo electroporation for improvement of therapeutic DNA vaccine against chronic hepatitis B infection  
**Lucyna Cova,** INSERM, France

11:40-12:00  
**Title:** A Synthetic multi-antigen approach targeting *Plasmodium falciparum* malaria  
**Bernadette Ferraro,** University of Pennsylvania, USA

12:00-12:20  
**Title:** Pneumococcal infections and vaccination  
**Birgitta Henriques-Normark,** Karolinska Institute, Sweden

12:20-12:40  
**Title:** Heat shock protein complex vaccines against mucosal pathogenic bacteria  
**Phil Sutton,** Murdoch Childrens Research Institute, Australia

Lunch Break 13:00-13:45 @ Multi Purpose Hall 2

**13:45-14:05**  
**Title:** Immunization with neuraminidase deficient influenza virus is highly immunogenic and non-pathogenic to wild type and immunocompromised mice  
**Alexandre M. Vieira Machado - Fiocruz,** Rene Rachou Research Center, Brazil

**14:05-14:25**  
**Title:** Design and evaluation of a novel OspA-based vaccine for the prevention of Lyme borreliosis  
**Andreas Meinke,** Valneva Austria GmbH, Austria

**14:25-14:45**  
**Title:** Therapeutic vaccines for drug-resistant tuberculosis  
**Tjip van der Werf,** University of Groningen, The Netherlands

14:45-15:05  
**Title:** Vaccination in risk groups with special focus on non-responsiveness to routine vaccines  
**Ursula Wiedermann,** Medical University of Vienna, Austria

15:05-15:25  
**Title:** Post challenging effects of new formulation of leishmania major antigen in Balb/c mice  
**Latifinia Afshineh,** Tehran University of Medical Sciences, Iran

**Coffee Break 15:25-15:40 @ Auditorium 3 Foyer**

15:40-16:00  
**Title:** Immunological studies on tetanus toxoid  
**Rakesh Kumar,** Serum Institute of India Limited, India

16:00-16:20  
**Title:** Process development and immunogenicity studies on a serogroup ‘X’ meningococcal polysaccharide conjugate vaccine  
**Srinivas Reddy,** Serum Institute of India Ltd, India

16:20-16:40  
**Title:** Th17 cells and evokes better memory T cell response than BCG  
**Javed N Agrewala,** CSIR - Institute of Microbial Technology, India

16:40-17:00  
**Title:** Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with *Mycobacterium tuberculosis*  
**Xueqiong Wu,** the 309th Hospital of Chinese PLA, China

17:00-17:20  
**Title:** Speciation of chromium in medicinal plants from selected farms in the vicinity of ferrochrome  
**Isiaka Alade Owolabi,** Tshwane University of Technology, South Africa

Panel Discussion 17:20-17:30

16:30-17:30  
**Special Session for Students:** Nikolai Petrovsky @ Community Hall 1-2

**Scientific writing, Journal review, Grant writing, Strategies for building a scientific career and Scientific careers outside of research**

Session-II @ Committee Room 6-7  
Cancer vaccines

**Session Chair:** Michael G. Hanna, Vaccinogen, Inc., USA

10:05-10:25  
**Title:** From viruses to tumor associated antigen cancer vaccines  
**Giulio Tarro,** Temple University Center for Biotechnology, USA

10:25-10:45  
**Title:** Measles Virus vaccine infects tumor cells and induces dendritic cells (DC) maturation and tumor antigen cross-presentation  
**Marc GREGOIRE,** Institut de Recherche en Santé Université de Nantes, INSERM, France

10:45-11:05  
**Title:** Personalized therapeutic cancer vaccine development to treat metastatic diseases  
**Periasamy Selvaraj,** Emory University, USA

**Coffee Break 11:05-11:20 @ Auditorium 3 Foyer**

11:20-11:40  
**Title:** Teaching self-destructing Salmonella new tricks to fight cancer  
**Wei Kong,** Arizona State University, USA
11:40-12:00 Title: DC targeting skin vaccines for improved cancer immunotherapy
Yvette van Kooyk, VU University Medical Center, The Netherlands
Title: Acceptability of human papillomavirus vaccine: A survey among master of business administration students in KwaZulu-Natal, South Africa
M E Hoque, University of KwaZulu-Natal, South Africa

Panel Discussion 12:20-12:30
AIDS/HIV vaccine

Title: Antigenicity, structure and immunogenicity of the HIV-1 trimeric envelope glycoprotein spike
Richard T Wyatt, The Scripps Research Institute La Jolla, USA

Lunch Break 12:50-13:35 @ Multi Purpose Hall 2

Title: Application of neutralization fingerprints in delineating antibody recognition in HIV-1 sera and antibody epitope prediction
Gwo-Yu Chuang, National Institutes of Health, USA
Title: The balance of cellular and humoral immunity determines the level of protection offered by an HIV vaccine in macaque models of HIV infection
Timothy Fouts, Profectus BioSciences, Inc., USA
Title: VAC-35 vaccine, a novel approach to the therapeutic management of HIV Infection. Overview of phase I and phase II clinical vaccine development programs
Raphael Ho Tsong Fang, InnaVirVax, France

Coffee Break 15:15-15:30 @ Auditorium 3 Foyer

15:30-15:50 Title: DNA vaccination against drug resistance in chronic viral infections, example of HIV-1
Maria ISAGULIANTS, Karolinska Institutet, Sweden; Riga Stradins Univeristy, Latvia
Title: Evaluation of immune response in small animal models by in vivo imaging
Stefan Petkov, Karolinska Institutet, Sweden
Title: Human clinical trial of SAV001 prophylactic HIV vaccine and a new strategy for the development of therapeutic HIV vaccine
Chil-Yong Kang, The University of Western Ontario, Canada

Panel Discussion 16:30-16:40
Vaccine antigen modeling

16:40-17:00 Title: Optimizing the delivery of novel immune potentiators within vaccine drug products
Mannohan Singh, Novartis Vaccines, USA
Title: Natural killer cell subsets display helper and suppressor effects in modulating host viral responses in vivo
William J. Murphy, UC Davis School of Medicine, USA

17:20-17:40 Title: Strategies of antigen retargeting for improvement of DNA vaccine performance
Elizaveta Starodubova, Karolinska Institutet, Sweden
Title: Cellular vaccines in Listeriosis: Role of the listeria antigen GAPDH
Carmen Alvarez-Dominguez, Instituto de Formacion e Investigacion Marques de Valdecilla, Spain
Title: Regulation of STING expression via the RIG-I dependent RNA sensing pathway
Rongtuan Lin, McGill University, Canada
Title: Cell engineering and antibiotic-free selection for vaccinal antigens production in E. coli: the ultimate sophistication to combine safety and productivity
Regis Sodoyer, Sanofi Pasteur, France
Title: Leishmania recombinant antigen modulates the macrophage effector functions synergizing anti-leishmanial effects of miltefosine to facilitate early clearance of intracellular parasites
Sunil K Arora, PGIMER, India

Day 3 September 26, 2014 @ Auditorium 3A

Session Chair: Malcolm E Thomas, Arbovax., Inc, USA

09:00-09:20 Title: Immunization and human rights
Obradovic Zarema, University of Sarajevo, Bosnia and Herzegovina
Title: SlgN's clinical immunomonitoring platform for the assessment of immune responses in cohort studies and clinical trials
Brian Abel, Singapore Immunology Network, Singapore
Title: Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children
Katie Ewer, University of Oxford, UK
10:00-10:20
Title: The common computer-based influenza vaccination/epidemics surveillance system: Challenges and opportunities for primary health care in EU countries
Ljiljana Majnaric Trtrica, JJ Strassmayer University, Croatia

10:20-10:40
Title: The development of tuberculosis subunit vaccine EAMMH and regulation of vaccine induced immune memory by Rapamycin
Bingdong Zhu, Lanzhou University, China

10:40-11:00
Title: Immunization programme in Indonesia: Overview—(Focusing on Streptococcus Pneumonia whole-cell vaccine)
Julitasari Sundoro, Indonesian Technical Advisory Group on Immunization, Indonesia

Panel Discussion 11:00-11:10

Coffee Break 11:10-11:25 @ Auditorium 3 Foyer

11:25-11:45
Title: Unique nanofabrication of antigens and adjuvants that effectively induces protective antibody and T cell responses
Frank J. Malinoski, Liquidia Technologies Inc., USA

11:45-12:05
Title: Development of a carbohydrate-based vaccine against meningococcal serogroup X infection
Francesco Berti, Novartis Vaccines, Italy

12:05-12:25
Title: Effect of the inclusion of “contemporary” B. pertussis strains in the vaccine composition on temporal trends in B. pertussis population
Tatjana Pljesa, Institute of Virology, Vaccines and Sera Torlak, Serbia

12:25-12:45
Title: Specificities of health economics in the area of vaccines evaluation
Maarten J Postma, University of Groningen, The Netherlands

12:45-13:05
Title: The effect of inclusion of “contemporary” B. pertussis strains in the vaccine composition on temporal trends in B. pertussis population
Tatjana Pljesa, Institute of Virology, Vaccines and Sera Torlak, Serbia

Panel Discussion 13:05-13:15

Lunch Break 13:15-14:00

14:00-14:20
Title: A novel approach to the development of arboviral vaccines for dengue and chikungunya virus
Malcolm E Thomas, Arbovax., Inc, USA

14:20-14:40
Title: Strategies toward developing a universal ExPEC vaccine capable of broad protection
Melha Mellata, Arizona State University, USA

14:40-15:00
Title: The vaxnella platform for oral recombinant vaccine delivery
Rocky M. Cranenburgh, Prokarium Ltd, UK

15:00-15:20
Title: Oral vaccine platform elicits neutralizing antibody responses to influenza
Sean Tucker, Vaxart, Inc., USA

15:20-15:40
Title: A rationally designed form of the TLR5 agonist, flagellin, supports superior immunogenicity of influenza B globular head vaccines
Langzhou Song, VaxInnate Corporation, USA

Coffee Break 15:40-15:55 @ Auditorium 3 Foyer

15:55-16:15
Title: Responsibility: A “first person ethics” for vaccination
Fermin J. Gonzalez-Melado, Pontifical Institute “John Paul II” for Studies on Marriage and Family, Spain

16:15-16:35
Title: Development of a truly improved whooping cough vaccine
Marcel Thalen, Iliad Biotechnologies, Scotland

16:35-16:55
Title: DNA vaccine against Leishmaniasis
Christiane Juhls, MOLOGEN AG, Germany

16:55-17:15
Title: Oral infections in Guinea Conakry
Sylvain Haba, Centre Des Soins Medico-Tradi-Spirituels Talithakoumi, Guinea Conakry

Panel Discussion 17:15-17:25

12:30-14:30 Poster Presentations @ Auditorium 3 Foyer Day-2

VAC-001
Title: Using NYVAC vectors as vaccine candidates for Leishmaniasis
Ernesto Mejias Perez, Centro Nacional de Biotecnologia, Spain

VAC-002
Title: Enhancement of antigen-specific CD4 T cell response through spacer modification in vaccinia virus promoters
Mauro Di Pilato, Centro Nacional de Biotecnologia, Spain

VAC-003
Title: IL-34 suppresses Candida albicans induced TNF-a production by M1 macrophages through down-regulation of Dectin-1 and TLR2 expression
Rong Xu, Cardiff University, UK

VAC-004
Title: Protection of chickens against Chlamydia psittaci challenge by mucosal immunization with the major outer membrane protein
Daisy Vanrompay, Ghent University, Belgium

VAC-005
Title: The single intradermal cervical comparative testand Johne’s disease ELISA diagnostics
Aideen Kennedy, Animal & Grassland Research and Innovation Centre, Ireland
VAC-006 Title: Antigen on nanoparticles enhances anti-tumor immune responses as well as humoral antibody responses in vivo
Junichiro Mizuguchi, Tokyo Medical University, Japan

VAC-007 Title: Hepatitis B immunization status of a miscellaneous population of workers
Frederic DESCHAMPS, University Hospital of Reims, France

VAC-008 Title: Retinoic acid promotes long lasting mucosal and systemic immune responses after mucosal priming and systemic boosting in mice
Silvia Vendetti, Istituto Superiore di Sanità, Italy

VAC-009 Title: Experimental chagas disease: Vaccination with Trypanosoma rangeli modulate the innate immune response in mice challenged with Trypanosoma cruzi
Beatriz Basso, National University of Cordoba, Argentina

VAC-010 Title: Trypanosoma cruzi infection in a mouse model of Chagas’ disease
Beatriz Basso, National University of Cordoba, Argentina

VAC-011 Title: Generation of genetically inactivated Salmonella Gallinarum ghost and evaluation of its potential as an effective inactivated vaccine candidate against fowl typhoid
Chetan V. Jawale, Chonbuk National University, Korea

VAC-012 Title: Increasing of alive plague vaccine efficiency
Chetan V. Jawale, Chonbuk National University, Korea

VAC-013 Title: Double-blind randomized placebo-controlled trial to evaluate cell-mediated immunity and safety of the herpes zoster vaccine in elderly patients with diabetes
Atsuko Hata, The Tazuke Kofukai Medical Research Institute, Japan

VAC-014 Title: Analysis of phage displayed antibody fragment - pros and cons of Phage ELISA and RISE methods
Barbara Kalenik, Institute of Biochemistry and Biophysics Polish Academy of Sciences, Poland

VAC-015 Title: HIV-1 Nef protein carries multiple epitopes suitable for induction of cellular immunity for an HIV vaccine in Africa
Athina KILPELAINEN, Karolinska Institutet, Sweden

VAC-016 Title: Retargeting of HIV reverse transcriptase to MHC class II processing improves its immunogenicity
Anastasia Latanova, Karolinska Institutet, Sweden

VAC-017 Title: Lipopolysaccharide of Coxiella burnetii. A promising candidate molecule in a search for a new Q fever vaccine
Rudolf Toman, Slovak Academy of Sciences, Slovak Republic

VAC-018 Title: Long-term immune response to Hepatitis B Virus (HBV) vaccine among type 1 diabetic students: Do they need a booster?
Engy M. El-Ghitany, Alexandria University, Egypt

VAC-019 Title: Bivalent candidate vaccine against HCV and HIV-1: Construction and biological evaluation
Mohammad Reza Aghasadegh, Pasteur Institute of Iran, Iran

VAC-020 Title: A local project about primary health care to improve the communication and the compliance in the elderly for vaccinal campaigns against influenza
Filippo de Nicolellis, Primary Health Care, Italy

VAC-021 Title: Expression profile of cytokine transcripts and Cell mediated immune response in peripheral blood mononuclear cells of sheep following vaccination of pentavalent bluetongue vaccine
Molalegne Bitew, Jimma University, Ethiopia

VAC-022 Title: In vitro molecular analysis of ribosomal initiation complexes assembly and RNA-protein interactions during the initiation of translation of a prototype Coxsackievirus B3 and a live-attenuated Sabin 3-like RNAs
Amira SOUII, Université de Tunis El Manar, Tunisia
Bookmark your dates

Asia Pacific Global Summit and Expo on Vaccines & Vaccination
June 01-03, 2015  Brisbane, Australia

Euro Global Summit and Expo on Vaccines & Vaccination
August 17-19, 2015  Birmingham, UK

Indo Global Summit and Expo on Vaccines & Vaccination
September 28-30, 2015  New Delhi, India

Dubai Global Summit and Expo on Vaccines & Vaccination
September 28-30, 2015  Dubai, UAE

American Global Summit and Expo on Vaccines & Vaccination
October 05-07, 2015  San Francisco, USA